Calamos Advisors
SYRE icon

Calamos Advisors’s Spyre Therapeutics SYRE Stock Holding History

Calamos Advisors’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.01M Buy
+11,323
New +$826K ﹤0.01% 753

Other funds holding SYRE

Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
EA
Ellsworth Advisors Hudson, Ohio $609M AUM 52.37% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
SO
STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return
AA
AlphaCentric Advisors San Juan, Puerto Rico $118M AUM

Calamos Advisors's SYRE Position: Q2 2026 in Review

Calamos Advisors opened a new position in Spyre Therapeutics (SYRE) in Q2 2026: 11,323 shares worth $1.01M. The stake represents ﹤0.01% of the portfolio and ranks #753 among its holdings.

29 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Calamos Advisors held 11,323 shares of Spyre Therapeutics worth $1.01M as of Q2 2026.
  • Spyre Therapeutics was a new Calamos Advisors position in Q2 2026.
  • Spyre Therapeutics made up ﹤0.01% of Calamos Advisors's portfolio in Q2 2026, its #753 holding.
  • 29 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Calamos Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.